STAINES-UPON-THAMES, England,
Dec. 8, 2017 /PRNewswire/
-- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global
specialty pharmaceutical company, will present on Monday, Jan. 8, 2018, at the 36th
Annual J.P. Morgan Healthcare Conference, which takes place at the
Westin St. Francis on Union Square, 335 Powell St., San Francisco.
Mark Trudeau, President and Chief
Executive Officer, and Matthew
Harbaugh, Executive Vice President and Chief Financial
Officer, will represent the company with a presentation at
7:30 a.m. Pacific time, followed by a
question-and-answer session from 8 a.m. to
8:25 a.m.
Individuals who cannot attend the meeting in person can find
webcast information at: http://www.mallinckrodt.com/investors. A
replay will also be available following the meeting.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical
products and therapies. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; and analgesics and
hemostasis products. The company's core strengths include the
acquisition and management of highly regulated raw materials and
specialized chemistry, formulation and manufacturing capabilities.
The company's Specialty Brands segment includes branded medicines
and its Specialty Generics segment includes specialty generic
drugs, active pharmaceutical ingredients and external
manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Investor Relations
Coleman N.
Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Media
Rhonda
Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-36th-annual-jp-morgan-healthcare-conference-300568562.html
SOURCE Mallinckrodt Pharmaceuticals